Search Videos and More
News
Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives
Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.
News
Study Finds Unexpected Role for Odd-Man-Out Member of CDK Protein Family
In the family of cyclin-dependent kinase (CDK) proteins, CDK5 always seemed to be a misfit. Despite being structurally similar to other CDKs, and despite the “cyclin” in its name, it did not participate in the family business of ushering cells through the cycle of growth and division.
News
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium.
News
Prostate Cancer Vaccines: What’s the Latest?
Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.?
News
Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor
CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.
News
Researchers Customize AI Tools for Digital Pathology
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions.
News
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
Document
Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
News
Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker
Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
News
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
News
New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines
In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.